ArticleMethodsX2024
Alamar Blue assay optimization to minimize drug interference and inter assay viability.
Article in MethodsX, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Upconverting Nanoparticles for Bimodal Luminescence and Magnetic Resonance Imaging of Langerhans Islets.Small science · 2026Article
- Article
- Development of Resazurin-Based Assay for Rapid Evaluation of Sodium Hypochlorite Tolerance inFoods (Basel, Switzerland) · 2026Article
- Plasma-Assisted UV Grafting of Thermo-Responsive Chitosan-Polymers · 2026Article
- TLR25 is endosomally located and responds toFrontiers in immunology · 2026Article
- A Thermosensitive Gel Containing Biodegradable Nanoparticles Carrying Calcium Hydroxide as Antibacterial Intracanal Therapy.International endodontic journal · 2026Article
- Injectable Piezoelectric Hydrogel for Vital Pulp Therapy.Journal of functional biomaterials · 2025Article
- Longan Flower Ethanol Extract,Biomedicines · 2025Article
- Sustainable production and antibacterial efficacy of silver nanoparticles on cellulose nanofibers from mushroom waste.RSC advances · 2025Article
- Divergent PTEN-p53 interaction upon DNA damage in a human thyroid organoid model with germline PTEN mutations.Endocrine-related cancer · 2025Article
- Biopolymers from Sugar Beet Molasses: Isolation, Characterization, and Bioactive Properties.ACS omega · 2025Article
- Enhanced Cell Proliferation, Migration, and Fibroblast Differentiation with Electrospun PCL-Zinc Scaffolds Coated with Fibroblast-Derived ECM.ACS omega · 2025Article
- Cytotoxicity of dilutions of bioceramic materials in stem cells of human exfoliated deciduous teeth.Journal of applied oral science : revista FOB · 2024Article
- Antimicrobial and Adjuvant Potencies of Di-Antibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
- Update of
Authors and funding
4 authors.
Funding
Abstract
Alamar Blue (AB) has become an increasingly popular reagent of choice for cell viability assays. We chose AB over other reagents such as MTT and Cell-Titer Glo due to its cost effectiveness and its ability to be a nondestructive assay. While analyzing the effect of osimertinib, an EGFR inhibitor on the non-small cell lung cancer cell line, PC-9, we noticed unexpected right-shifts of dose response curves as compared to the curves obtained by Cell Titer Glo assay. Here, we describe our modified AB assay method to avoid that right shift in dose response curves.•Removal of the drug containing medium prior to AB addition eliminated the falsely increased readings, giving comparable dose response curves as determined by Cell Titer Glo assay.•Plate-to-plate variability can be minimized by adding an appropriate concentration of a common fluorescence calibration standard to the assay plates to calibrate fluorimeter sensitivity.•Alamar Blue can be used as a continuous longitudinal assay to monitor cell growth or recovery from drug toxicity over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.